220 related articles for article (PubMed ID: 1730031)
21. Characterization of the interaction between plasminogen and staphylokinase.
Lijnen HR; De Cock F; Van Hoef B; Schlott B; Collen D
Eur J Biochem; 1994 Aug; 224(1):143-9. PubMed ID: 8076635
[TBL] [Abstract][Full Text] [Related]
22. Fibrin-targeted plasminogen activation by plasminogen activator, PadA, from Streptococcus dysgalactiae.
Singh S; Bhando T; Dikshit KL
Protein Sci; 2014 Jun; 23(6):714-22. PubMed ID: 24639287
[TBL] [Abstract][Full Text] [Related]
23. [Inhibition of the process of Glu-plasminogen activation by tissue activator with fibrin, DDE-complex, and D-dimer using alpha-2-antiplasmin].
Hrynenko TV; Zadorozhna MB; Platonova TM; Volkov HL
Ukr Biokhim Zh (1999); 2005; 77(5):45-51. PubMed ID: 16846069
[TBL] [Abstract][Full Text] [Related]
24. Activated thrombin-activatable fibrinolysis inhibitor reduces the ability of high molecular weight fibrin degradation products to protect plasmin from antiplasmin.
Schneider M; Brufatto N; Neill E; Nesheim M
J Biol Chem; 2004 Apr; 279(14):13340-5. PubMed ID: 14715654
[TBL] [Abstract][Full Text] [Related]
25. The role of alpha 2-antiplasmin in the inhibition of clot lysis in newborns and adults.
Ries M; Klinge J; Rauch R; Keuper H; Harms D
Biol Neonate; 1996; 69(5):298-306. PubMed ID: 8790908
[TBL] [Abstract][Full Text] [Related]
26. The molecular form of alpha 2-antiplasmin with affinity for plasminogen is selectively bound to fibrin by factor XIII.
Kluft C; Los P; Jie AF
Thromb Res; 1984 Feb; 33(4):419-25. PubMed ID: 6710441
[TBL] [Abstract][Full Text] [Related]
27. Mechanism of action and thrombolytic potential of staphylokinase.
Lijnen HR
Verh K Acad Geneeskd Belg; 1995; 57(4):303-14. PubMed ID: 8571666
[TBL] [Abstract][Full Text] [Related]
28. Identification of a site in fibrin(ogen) which is involved in the acceleration of plasminogen activation by tissue-type plasminogen activator.
Nieuwenhuizen W; Vermond A; Voskuilen M; Traas DW; Verheijen JH
Biochim Biophys Acta; 1983 Oct; 748(1):86-92. PubMed ID: 6684481
[TBL] [Abstract][Full Text] [Related]
29. Noncovalent interaction of alpha(2)-antiplasmin with fibrin(ogen): localization of alpha(2)-antiplasmin-binding sites.
Tsurupa G; Yakovlev S; McKee P; Medved L
Biochemistry; 2010 Sep; 49(35):7643-51. PubMed ID: 20687529
[TBL] [Abstract][Full Text] [Related]
30. Secondary-site binding of Glu-plasmin, Lys-plasmin and miniplasmin to fibrin.
Suenson E; Thorsen S
Biochem J; 1981 Sep; 197(3):619-28. PubMed ID: 6459779
[TBL] [Abstract][Full Text] [Related]
31. [Binding of alpha-2-antiplasmin with fibrinogen/fibrin and their fragments independent of factor XIII].
Zadorozhna MB; Hrynenko TV; Iusova OI; Volkov HL
Ukr Biokhim Zh (1999); 2004; 76(5):71-7. PubMed ID: 16100900
[TBL] [Abstract][Full Text] [Related]
32. Like fibrin, (DD)E, the major degradation product of crosslinked fibrin, protects plasmin from inhibition by alpha2-antiplasmin.
Lee AY; Fredenburgh JC; Stewart RJ; Rischke JA; Weitz JI
Thromb Haemost; 2001 Mar; 85(3):502-8. PubMed ID: 11307822
[TBL] [Abstract][Full Text] [Related]
33. Cross-linking of plasminogen activator inhibitor 2 and alpha 2-antiplasmin to fibrin(ogen).
Ritchie H; Lawrie LC; Crombie PW; Mosesson MW; Booth NA
J Biol Chem; 2000 Aug; 275(32):24915-20. PubMed ID: 10816585
[TBL] [Abstract][Full Text] [Related]
34. Effects of alpha 2-plasmin inhibitor on plasminogen activation by staphylokinase/plasminogen complex.
Okada K; Nonaka T; Matsumoto H; Fukao H; Ueshima S; Matsuo O
Thromb Res; 1994 Oct; 76(2):211-20. PubMed ID: 7863470
[TBL] [Abstract][Full Text] [Related]
35. [Features of the interaction between alpha2-antiplasmin and plasminogen/plasmin].
Hrynenko TV; Iusova OI; Zadorozhna MB; Makohonenko IeM
Ukr Biokhim Zh (1999); 2002; 74(6):83-90. PubMed ID: 12924019
[TBL] [Abstract][Full Text] [Related]
36. The mechanism of activation of plasminogen at the fibrin surface by tissue-type plasminogen activator in a plasma milieu in vitro. Role of alpha 2-antiplasmin.
Rouy D; Anglés-Cano E
Biochem J; 1990 Oct; 271(1):51-7. PubMed ID: 1699517
[TBL] [Abstract][Full Text] [Related]
37. On the specific interaction between the lysine-binding sites in plasmin and complementary sites in alpha2-antiplasmin and in fibrinogen.
Wiman B; Lijnen HR; Collen D
Biochim Biophys Acta; 1979 Jul; 579(1):142-54. PubMed ID: 157166
[TBL] [Abstract][Full Text] [Related]
38. Introduction of lysine and clot binding properties in the kringle one domain of tissue-type plasminogen activator.
Bakker AH; van der Greef W; Rehberg EF; Marotti KR; Verheijen JH
J Biol Chem; 1993 Sep; 268(25):18496-501. PubMed ID: 8395505
[TBL] [Abstract][Full Text] [Related]
39. Post-thrombolysis haemostasis changes after rt-PA treatment in acute cerebral infarct. Correlations with cardioembolic aetiology and outcome.
Sun X; Berthiller J; Derex L; Trouillas P; Diallo L; Hanss M
J Neurol Sci; 2015 Feb; 349(1-2):77-83. PubMed ID: 25619569
[TBL] [Abstract][Full Text] [Related]
40. A fast-acting, modular-structured staphylokinase fusion with Kringle-1 from human plasminogen as the fibrin-targeting domain offers improved clot lysis efficacy.
Wu SC; Castellino FJ; Wong SL
J Biol Chem; 2003 May; 278(20):18199-206. PubMed ID: 12646571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
